Loading
MYH9 (Myosin-9) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Head and neck squamous cell carcinoma, Breast cancer, Colorectal cancer and 5 more.
Cellular myosin that appears to play a role in cytokinesis, cell shape, and specialised functions such as secretion and capping. Required for cortical actin clearance prior to oocyte exocytosis. Promotes cell motility in conjunction with S100A4.
Open Targets scores its association with cancer at 0.74 (direct and indirect evidence; datatypes affected pathway 0.57, literature 0.99, genetic association 0.00, somatic mutation 0.88, animal model 0.59). IntOGen calls it a driver in 11 cohorts (3 activating, 8 loss-of-function), covering Basal Cell Carcinoma, Bladder Urothelial Carcinoma, Invasive Breast Carcinoma, Colorectal Adenocarcinoma, Oesophageal Adenocarcinoma, Head and Neck Squamous Cell Carcinoma and others.
In plain words · MYH9 (Myosin-9) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Head and neck squamous cell carcinoma, Breast cancer, Colorectal cancer and 5 more.
MYH9 (Myosin-9) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Head and neck squamous cell carcinoma, Breast cancer, Colorectal cancer and 5 more.
Cellular myosin that appears to play a role in cytokinesis, cell shape, and specialised functions such as secretion and capping. Required for cortical actin clearance prior to oocyte exocytosis.
No product in this corpus aims at MYH9 yet. Because the protein is lost rather than overactive, drugs either restore its function or exploit the weakness its loss leaves (synthetic lethality).
First described 1990. Earliest sequence paper UniProt cites for the protein: Saez C.G. et al, Proc. Natl. Acad. Sci. U.S.A, 1990, "Human nonmuscle myosin heavy chain mRNA: generation of diversity through alternative polyadenylylation". Source.
Sources: HGNC HGNC:7579 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P35579 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000100345 (association with cancer (MONDO_0004992) 0.74; per-cancer scores at or above 0.5: colorectal cancer 0.54, gastric cancer 0.54, ovarian cancer 0.54, melanoma 0.55, skin cancer 0.54, breast cancer 0.59 (GraphQL API, CC0)); IntOGen MYH9 (driver in 11 cohorts (Act 3, LoF 8); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Cellular myosin that appears to play a role in cytokinesis, cell shape, and specialised functions such as secretion and capping. Required for cortical actin clearance prior to oocyte exocytosis. Promotes cell motility in conjunction with S100A4. During cell spreading, plays an important role in cytoskeleton reorganisation, focal contact formation (in the margins but not the central part of spreading cells), and lamellipodial retraction; this function is mechanically antagonised by MYH10. Location: Cytoplasm, cytoskeleton; Cytoplasm, cell cortex; Cytoplasmic vesicle, secretory vesicle, Cortical granule; Cell membrane (UniProt). Locus 22q12.3 (HGNC).
Query for this target: (TITLE:"MYH9" OR ABSTRACT:"MYH9" OR TITLE:"myosin heavy chain 9" OR ABSTRACT:"myosin heavy chain 9" OR TITLE:"Myosin-9" OR ABSTRACT:"Myosin-9" OR TITLE:"NMMHCA" OR ABSTRACT:"NMMHCA" OR TITLE:"NMHC-II-A" OR ABSTRACT:"NMHC-II-A" OR TITLE:"EPSTS" OR ABSTRACT:"EPSTS") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about MYH9, not a curated reading list.